China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced positive topline results from the Phase III study for its core candidate drug TAB014 in the treatment of wet (neovascularization) age-related macular degeneration (wAMD). The study successfully met all primary and key secondary endpoints, marking a significant milestone in the development of this potential therapy.
TAB014: A Promising Recombinant Anti-VEGF Antibody
TAB014 is a recombinant anti-VEGF (vascular endothelial growth factor) antibody currently in development for the treatment of wAMD, retinal vein occlusion (RVO), choroidal neovascularization (CNV), and other eye diseases. This drug candidate has shown promise in addressing the unmet medical needs of patients suffering from these vision-threatening conditions.
Licensing Deal and Regional Rights for TAB014
In January 2017, a licensing deal was struck between Tot Biopharmaceutical International Co., Ltd (HKG: 1875) and Lee’s Pharma, granting the latter clinical and commercial development rights to TAB014 in China, including mainland China, Hong Kong, and Macau. This agreement highlights the strategic importance of TAB014 in the regional pharmaceutical market and underscores the potential for it to become a standard treatment for wAMD and related eye diseases.-Fineline Info & Tech
